Ventripoint Diagnostics Announces Collaboration with Summit Sciences

(TheNewswire)

Engagement to develop economic andROI models

Toronto, Ontario – TheNewswire - December 18, 2025 -Ventripoint Diagnostics Ltd. ("Ventripoint" orthe "Company"), (TSXV:VPT; OTC:VPTDF) a leader in AI-enhancedcardiac imaging solutions, today announced the engagement of DanaFriesen and Summit Sciences, a specialized consulting firm, to createmore sophisticated, customer-centric financial andreturn-on-investment (ROI) models. This strategic partnership aims toequip healthcare providers with enhanced tools to evaluate theeconomic benefits of adopting Ventripoint's innovative VMS+technology for cardiac diagnostics.

The collaboration will focus on refining financialmodeling frameworks that highlight the cost savings, operationalefficiencies, and clinical outcomes associated with Ventripoint'sAI-driven 3D heart modeling system. By integrating advanced analyticsand real-world data, the new models will provide tailored insights forhospitals, clinics, and cardiology practices, demonstrating clear ROIthrough process improvement, better accuracy in heart assessments, andoptimized resource allocation.

"We are excited to partner with Dana and SummitSciences to elevate our financial modeling capabilities," saidHugh MacNaught, President & CEO of Ventripoint Diagnostics."Dana's extensive expertise in healthcare transformation,combined with Summit Sciences' proven track record in data-drivenconsulting, will enable us to deliver even more compelling valuepropositions to our customers. This initiative underscores ourcommitment to not only advancing cardiac care through technology butalso ensuring that our solutions make strong economic sense forhealthcare providers worldwide."

“We believe that Ventripoint’s VMS+ system canprovide real benefits to patients, healthcare providers, andpayors,” commented Dana Friesen, CEO of Summit Sciences. “Bycreating new models based on real-world data, Ventripoint will be ableto accelerate the pace of commercializing VMS+ while expanding globalaccess to advanced cardiac imaging. Our history of working inpartnership with a variety of partners and delivery models, includingindigenous health networks and community-based models of care acrossCanada, the United States, and Latin America provides experience indelivering culturally sensitive  and appropriate solutions addressingcost effectiveness and local accessibility. As an economic researchorganization, we are equally focused on uncovering both thepatient-level outcomes and the measurable financial benefits VMS+™technology can deliver—ensuring that innovation improves care whilestrengthening the economic sustainability of healthcaresystems.”

Dana Friesen brings over 15 years of experience infinancial analysis and ROI optimization within the medical device andhealthcare sectors. Summit Sciences specializes in deliveringtransformational insights and solutions to clients, enabling them totranslate complex data into actionable business strategies.

This engagement is part of Ventripoint's broaderstrategy to accelerate market adoption of its VMS+ platform, whichuses artificial intelligence to generate accurate 3D models of theheart from standard 2D ultrasound images, offering a faster, moreaffordable and accessible alternative to traditional MRI scans.

About Ventripoint DiagnosticsLtd.

Ventripoint is an industry leaderin the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary Knowledge Based Reconstruction technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all of Ventripoint's productsthat guide our future developments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe, and Canada.

About Summit Sciences

Over the past two decades Summit Sciences has workedwith numerous clinical agencies and delivered billions in lifetimepartner savings. Summit’s research services provide hospitals,manufacturers, and healthcare organizations with the critical dataneeded to make informed decisions about technology adoption,implementation strategies, and performance optimization.  Summitemploys advanced research methodologies combining clinical outcomeanalysis, operational efficiency metrics, and financial impactassessment to deliver actionable insights that improve patient carewhile optimizing resource utilization and demonstrating clear returnon investment.

For further information, pleasecontact:

Hugh MacNaught

hmacnaught@ventripoint.com

604-671-4201

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' andsimilar expressions are intended to identify forward-lookinginformation or statements. The forward-looking statements andinformation are based on certain key expectations and assumptions madeby the Company. Although the Company believes that the expectationsand assumptions on which such forward-looking statements andinformation are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCompany can give no assurance that they will prove to becorrect.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company'smost recent annual management's discussionand analysis that is available on the Company's profile on SEDARat www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.